Get started
Work

The First‐in‐class Anti‐cd47 Antibody Hu5f9‐g4 + Rituximab Induces Durable Responses in Relapsed/refractory Dlbcl and Indolent Lymphoma: Interim Phase 1b/2 Results

Year: 2019
Type: article
Study design: Clinical Trial
DOI: 10.1002/hon.57_2629
Authors: R. Advani, N.L. Bartlett, S.M. Smith, M. Roschewski, L. Popplewell, I. Flinn, G. Collins, N. Ghosh, A. LaCasce, A. Asch, J. Kline, M. Kesevan, T. Tran, J. Lynn, J. Huang, B. Agoram, J. Volkmer, C.H. Takimoto, M.P. Chao, A. Mehta
Institutions: Stanford Medicine, Stanford University, Washington University in St. Louis, University of Chicago, National Institutes of Health, National Cancer Institute, City Of Hope National Medical Center, City of Hope, Sarah Cannon, University of Oxford, Dana-Farber Cancer Institute, University of Oklahoma, University of Alabama at Birmingham, UAB Medicine
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W2952493398
FWCI: 3.77
Cites:
Cited by: 29
Related to: 10